Showing 321 - 340 results of 41,162 for search '(((( 5 c decrease ) OR ( 2 fold decrease ))) OR ( 50 ((nn decrease) OR (a decrease)) ))', query time: 0.88s Refine Results
  1. 321

    Data_Sheet_1_Marathon Running Increases Synthesis and Decreases Catabolism of Joint Cartilage Type II Collagen Accompanied by High-Energy Demands and an Inflamatory Reaction.PDF by José A. Hernández-Hermoso (11545663)

    Published 2021
    “…Accompanied by an increase in type II collagen cartilage fibrils synthesis (sPIINP increase) and a decrease in its catabolism (sC2C decrease), without changes in non-collagenous cartilage metabolism (sCOMP, sC846, and sYKL-40). …”
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326

    Most miRNAs in Ago1 RISC are stable with age whereas transposon siRNAs in Ago2 RISC decrease with age. by Siobhan Gartland (14129274)

    Published 2022
    “…(B) miRNAs in Ago1 RISC from old and young females are plotted as percentage of mapped reads. miR-34-5p and miR-14-3p do not change by 2-fold. miR-318-3p and miR-994-5p decrease by 2-fold with age. …”
  7. 327
  8. 328

    Fig 5 - by Marian Adan (16641634)

    Published 2024
    Subjects:
  9. 329
  10. 330

    S5 File - by Marian Adan (16641634)

    Published 2024
    Subjects:
  11. 331
  12. 332
  13. 333

    Cytoskeletal Drugs Modulate Off-Target Protein Folding Landscapes Inside Cells by Caitlin M. Davis (5642156)

    Published 2020
    “…The decreased compactness and folding stability of PGK could be explained by the decreased extent of crowding induced by these drugs. …”
  14. 334
  15. 335

    GCase activity is significantly decreased in the brain and liver of the homozygous <i>GBA1</i> D409V KI mouse model at 4, 8, and 12 months of age. by Nicole K. Polinski (10947787)

    Published 2021
    “…In whole brain homogenate (A,C) and liver homogenate (B,D), GCase activity is significantly decreased in the <i>GBA1</i> D409V KI homozygous (HOM) mice as compared to C57Bl/6 wild type (WT) mice (n = 7/group). …”
  16. 336
  17. 337
  18. 338
  19. 339

    Design, Synthesis, and Biological Evaluation of [1,2,5]Oxadiazolo[3,4‑<i>b</i>]pyridin-7-ol as Mitochondrial Uncouplers for the Treatment of Obesity and Metabolic Dysfunction-Assoc... by Mary A. Foutz (20361830)

    Published 2024
    “…Pharmacokinetic studies indicated a half-life of 2 h, <i>C</i><sub>max</sub> of 35 μM, and no observed adverse effects at 1,000 mg kg<sup>–1</sup> dose in mice. …”
  20. 340